sub:assertion {
  d:DB06144 v:identifier "DB06144" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB06144" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB06144> ;
    dv:drugbank-id "DB06144" ;
    dv:x-atc <http://bio2rdf.org/atc:N05AE03> ;
    dv:x-cas <http://bio2rdf.org/cas:106516-24-9> ;
    dv:x-chebi <http://bio2rdf.org/chebi:9122> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:54229> ;
    dv:x-gtp <http://bio2rdf.org/gtp:98> ;
    dv:x-iuphar <http://bio2rdf.org/iuphar:98> ;
    dv:x-kegg <http://bio2rdf.org/kegg:C07567> , <http://bio2rdf.org/kegg:D00561> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164784002> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:60149> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46504717> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Sertindole> ;
    dct:description "Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market."@en ;
    dct:identifier "drugbank:DB06144" ;
    dct:title "Sertindole"@en ;
    a dv:Drug ;
    rdfs:label "Sertindole [drugbank:DB06144]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB06144> .
}